SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the community actively debates whether the recent price action marks a breakout phase or a trap, fueled by intense liquidations of short positions. Sentiment remains polarized between bulls targeting significant upside momentum and bears pointing to historical resistance and institutional leverage as signals of potential consolidation.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports of an unsolicited $56 billion bid to acquire eBay, sparking intense debate among investors regarding the feasibility of the deal, the potential for massive stock dilution, and the long-term strategic vision of CEO Ryan Cohen. While some community members are betting on a massive short squeeze and a fundamental transformation, others remain deeply skeptical, viewing the proposal as a high-risk gamble or a distraction that could lead to significant downside.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing market attention as bulls attempt to break through key resistance levels, with community discourse fueled by speculation around institutional developments and hopes for a sustained rally. While sentiment remains highly polarized, investors are actively debating the token's potential to front-run broader crypto market movements and its long-term viability as a digital asset.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to explosive AI-driven demand for NAND flash memory, which has led to capacity being largely sold out through 2026 and prompted major analyst price target hikes. Community discussion is heavily divided between bulls celebrating a structural growth supercycle and bears warning that the stock's massive rally may lead to a sharp correction.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense bullish momentum and short-squeeze speculation as traders anticipate upcoming earnings, driven by a high short interest and aggressive institutional position-building. The community is actively debating the stock's potential for a massive rally while navigating volatility caused by the heavy short-selling environment and recent industry-wide optimism regarding voice AI demand.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is currently a focal point of intense community debate, with proponents highlighting the launch of the LitVM layer and potential institutional inflows, while skeptics point to sustained underperformance relative to broader market assets. Investors remain divided between those viewing the coin as an undervalued, reliable payment network coiling for a major breakout and others who see it as a lagging asset with declining dominance.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

GameStop is trending after reports surfaced of a potential takeover bid for eBay, sparking intense debate among retail traders regarding the feasibility of the deal and the valuation of both companies. While some community members are speculating on the strategic synergy between the two, others remain highly skeptical of the financial logistics, leading to significant volatility in sentiment.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a viral profile highlighting the company's pivot into a high-margin software powerhouse, particularly its critical role in the 'Machine Economy' through partnerships with NVIDIA and its QNX operating system. The community is actively discussing a potential breakout fueled by consistent profitability, massive royalty backlogs, and growing institutional interest in the company's position as a secure backbone for autonomous transit and physical AI.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The PEPE community is highly active, with traders closely monitoring its price action around key resistance levels while debating the long-term impact of potential institutional ETF filings. Discussions remain centered on collective accumulation strategies and comparisons to other meme coin cycles as investors watch for signals of a broader market breakout.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing heightened community engagement as investors debate its potential for a breakout, with many users expressing confident, long-term sentiment alongside skeptical voices highlighting scam-related news and historical price volatility. The conversation remains polarized, with bullish supporters actively calling for supply burns and ecosystem adoption while others criticize the token as a stagnant asset.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The deals involve the purchase of KKDA-FM, a longtime urban contemporary station known for hip-hop and R&amp;B, and KRNB, which airs an urban adult contemporary format.</li><li>Both transactions are subject to approval by the Federal Communications Commission.</li><li>The acquisition would bolster Urban One’s already significant footprint in the Dallas-Fort Worth market.</li></ul> Shares of Urban One, Inc. (UONE) jumped 38% on Friday after the company announced that it has reached agreements to acquire two leading Dallas-Fort Worth radio stations from Service Broadcasting Group, LLC, while selling one of its own local properties.The deals involve the purchase of KKDA-FM, a longtime urban contemporary station known for hip-hop and R&amp;B, and KRNB, which airs an urban adult contemporary format. In a related transaction, Urban One will divest KZMJ, its urban adult contemporary outlet, to Fuzion Dallas.<h2 class="st-heading-2">UONE’s Acquisition Rationale</h2>Both transactions are subject to approval by the Federal Communications Commission and other customary closing conditions. The media firm did not divulge the financial terms of the agreement.“This transaction is accretive and advances our consolidation strategy by scaling our presence in high-growth regions where our target audience is most concentrated,” said Alfred C. Liggins III, president and chief executive officer of Urban One.The acquisition would bolster Urban One’s already significant footprint in the Dallas-Fort Worth market, one of the country’s largest and fastest-growing urban radio markets. The moves reflect Urban One’s ongoing strategy of portfolio optimization and market consolidation in key urban centers. The company’s Radio One division currently operates 74 broadcast stations across 13 top African American markets nationwide.<h2 class="st-heading-2">How Did UONE Retail Traders React?</h2>On Stocktwits, retail sentiment around UONE stock jumped from ‘bearish’ to ‘normal’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user said that they have started a stop position on the stock.<stembedurl>https://www.stocktwits.com/FlashTrad3r/message/652044435</stembedurl>Another voiced optimism for a higher rally.<stembedurl>https://www.stocktwits.com/Richard_Greenfield/message/652046188</stembedurl><a href="https://stocktwits.com/symbol/UONE">UONE stock</a> has fallen 58% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-li-xpev-who-among-the-chinese-ev-maker-trio-delivered-most-vehicles-in-april/cZQVgaEReeV">NIO Vs. LI Vs. XPEV: Who Among The Chinese EV Maker Trio Delivered Most Vehicles In April?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did UONE Stock Rally 38% Today?

Urban One announced that it has reached agreements to acquire two leading Dallas-Fort Worth radio stations from Service Broadcasting Group, LLC, while selling one of its own local properties to Fuzion Dallas, LLC. 

Equity

<ul class="summary-bullets"><li>The $30 million net proceeds from the placement will allow the company to advance its clinical pipeline, Cue said.</li><li>Cue also announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases.</li><li>The company named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.</li></ul> Shares of Cue Biopharma (CUE) jumped nearly 100% after-hours on Thursday after the clinical-stage biotech company announced changes collectively aimed at strengthening its cash position, expanding its clinical pipeline, and bringing in new leadership.The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.<h2 class="st-heading-2">$30 Million Private Placement Bolsters Balance Sheet</h2>Cue Biopharma entered into a securities purchase agreement with certain accredited investors for a private placement expected to raise gross proceeds of approximately $30 million before fees and expenses.The company stated it will use the net proceeds to advance its clinical pipeline, support working capital, and fund general corporate purposes. The transaction is expected to close on or about May 4, 2026, subject to customary closing conditions.<h2 class="st-heading-2">Exclusive License Adds To Pipeline</h2>Cue Biopharma further announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases. The license covers all territories except mainland China, Hong Kong, Macau, and Taiwan.Cue plans to advance the asset into further studies, with near-term clinical data expected from an ongoing mid-stage trial in chronic spontaneous urticaria during the second half of 2026.The company said that it will pay Ascendant $15 million upfront as a license fee, followed by up to an aggregate of $676.5 million in additional potential payments upon the achievement of certain milestones, in addition to tiered royalties on future sales of the drug.<h2 class="st-heading-2">Veteran Executive Shao-Lee Lin Named New CEO</h2>Cue Biopharma also named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.Lin previously founded and led the pharma company ACELYRIN, where she raised over $1 billion in capital and took the company public at a valuation exceeding $2 billion within three years. She has held senior roles at Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen.<h2 class="st-heading-2">How Did CUE Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user voiced optimism on the licensing deal.<stembedurl>https://www.stocktwits.com/AlertsAndNews/message/651957851</stembedurl>Another use voiced hopes for the stock rallying as high as $50, implying a potential rally of about 100% from the stock’s last close.<stembedurl>https://www.stocktwits.com/Aburose/message/651956517</stembedurl>A third user opined that the after-hours rally was a result of manipulation and a short squeeze.<stembedurl>https://www.stocktwits.com/Erect4tech/message/651956070</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 35% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/meta-ceo-links-stock-drop-to-higher-capex-plans-team-cuts-and-more-apps-report/cZBMpgSReIX">Meta CEO Links Stock Drop To Higher Capex, Plans Team Cuts And More Apps: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cue Biopharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? 

Cue Biopharma company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.

The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.


<ul class="summary-bullets"><li>The CEO will present findings from Edesa’s late-stage study of EB05, being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS), at the conference.</li><li>The company expects to start recruiting patients for its mid-stage vitiligo trial starting in mid-2026.</li><li>According to data from &nbsp;Koyfin, both analysts covering EDSA rate it ‘Buy.’</li></ul> Shares of Edesa Biotech (EDSA) rallied 54% higher on Monday, closing at a new 52-week high of $11.17. &nbsp;The rally comes ahead of the company CEO’s upcoming presentation at the ATS 2026 Respiratory Innovation Summit (RIS), organized by the American Thoracic Society (ATS), on May 15. The CEO will present findings from Edesa’s late-stage study of EB05, being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS), at the conference.In February, Edesa reported positive late-stage trial results for EB05. The company said that the drug demonstrated statistically significant reductions in 28-day mortality across a broader patient population in the trial. &nbsp;<h2 class="st-heading-2">Remaining Pipeline</h2>Edesa is a biopharmaceutical company developing treatments for inflammatory and immune-related diseases. The company’s pipeline includes EB06, being developed as a therapy for vitiligo, and EB01 for the treatment of moderate-to-severe chronic Allergic Contact Dermatitis.Last month, the company said that it expects to start recruiting patients for its mid-stage vitiligo trial starting in mid-2026. The trial is aimed at evaluating the safety and efficacy of EB06 compared to adults in adults with with generalized vitiligo.<h2 class="st-heading-2">Analyst Takeaway</h2>According to data from &nbsp;Koyfin, both analysts covering EDSA rate it ‘Buy.’The average 12-month price target on the stock is $11, representing a potential downside of about 2%.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around EDSA stock jumped from ‘bearish’ to ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user speculated a buyout price for the company.<stembedurl>https://www.stocktwits.com/VoxChameleon/message/651560849</stembedurl><a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has gained 365% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-overvalued-fund-manager-demands-math-on-3000-dollar-bull-targets/cZBV5nGRePu">TSLA Overvalued? Fund Manager Demands Math on $3,000 Bull Targets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?

The rally comes ahead of the company CEO’s upcoming presentation at the ATS 2026 Respiratory Innovation Summit (RIS) and other pipeline catalysts.

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-cap Biotech?

<ul class="summary-bullets"><li>Amesite also stated that it has agreed to issue Series A-1 and Series A-2 warrants to purchase an additional 1.4 million shares of its common stock at an exercise price of $1.435 per share.</li><li>In addition to the direct offering, Amesite also announced that it has entered into definitive agreements for a private placement of its common stock.</li><li>This includes 696,866 shares and up to 1.4 million warrants, both priced at $1.435 per share.</li></ul>Shares of Amesite Inc. (AMST) fell more than 32% on Monday before paring some of the losses after the company announced a direct offering of its common stock.Amesite stated that it has entered into definitive agreements for the purchase and sale of 696,866 shares of its common stock at a price of $1.435 per share. This is at a discount of more than 9% to Amesite’s closing price on Friday.<a href="https://stocktwits.com/symbol/AMST">Amesite shares</a> were down nearly 25% in Monday’s midday trade.<h2 class="st-heading-2">Amesite Issues Warrants For 1.4 Million Additional Shares</h2>Amesite also stated that it has agreed to issue Series A-1 and Series A-2 warrants to purchase an additional 1.4 million shares of its common stock.These warrants have an exercise price of $1.435 per share and will be exercisable on the effective date of shareholder approval.The Series A-1 warrants will expire five years after the later of the Resale Registration Statement’s effective date or stockholder approval, while the Series A-2 warrants will expire 18 months after the later of those same two dates.In addition to the direct offering, Amesite also announced that it has entered into definitive agreements for a private placement of its common stock. This includes 696,866 shares and up to 1.4 million warrants, both priced at $1.435 per share.Amesite stated that the offerings are expected to close on or about April 28, 2026. The company expects gross proceeds of up to $2 million from the direct offering. The potential gross proceeds from the warrants, if fully exercised, will be approximately $4 million.Amesite intends to use the proceeds of the offering to meet its working capital requirements and for other general corporate purposes.The company also announced the withdrawal of its public offering.<h2 class="st-heading-2">What Does Amesite Do?</h2>Amesite is a Detroit-based AI-driven company behind the NurseMagic platform, which streamlines documentation for nurses and caregivers.The company touts that NurseMagic can reduce the documentation process from 20 minutes to 20 seconds. It added that the platform is used across more than 100 professions, serving users across 50 states and 21 countries.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AMST">Amesite</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user stated that the selloff in Amesite stock makes them want to invest more in the company.<stembedurl>https://stocktwits.com/Klinsmann/message/651501760</stembedurl><a href="https://stocktwits.com/symbol/AMST">AMST stock</a> is down 36% year-to-date and 43% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 33% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/orka-stock-soaring-psoriasis-trial-btig-hikes-price-target-by-94/cZBNtVBReP1">ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bear Market and falling chart - stock photo

AMST Plummets 32% After Announcing $6M Concurrent Direct Offering, Private Placement

Amesite stated that it has entered into definitive agreements to purchase and sell 696,866 shares of its common stock at a price of $1.435 per share.

<ul class="summary-bullets"><li>Wearable Devices stated that its partnership aims to integrate its products, Mudra Band and Mudra Link, with Meta-Bounds’ products to enable spatial interaction.</li><li>This partnership will target end consumers in the short term and enterprise users in the long term.</li><li>Wearable Devices stated that the short-term focus of the partnership will include developing preliminary wristband controls for AR glasses.&nbsp;</li></ul>Shares of Wearable Devices (WLDS) climbed nearly 115% on Monday before paring some of the gains, registering the best intraday gains in more than seven months after the company announced a collaboration with Meta-Bounds Inc. for intuitive neural control for augmented reality (AR) glasses.Wearable Devices also announced that it will develop solutions to make it easier for consumers to use AR glasses and create a seamless user experience.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/WLDS">Wearable Devices shares</a> were up more than 87% in Monday morning’s trade.<h2 class="st-heading-2">Partnership To Bring Wearable Devices’ Products To More Users</h2>Wearable Devices stated that its partnership aims to integrate its products, Mudra Band and Mudra Link, with Meta-Bounds’ products to enable spatial interaction. This partnership will target end consumers in the short term and enterprise users in the long term, the company stated.Wearable Devices stated that the short-term focus of the partnership will include developing preliminary wristband controls for AR glasses. This will allow users to control their AR experience using wrist gestures.Over the long term, the company stated that it has developed a primary commercial model to support its global scaling ambitions and cater to the diverse needs of Meta-Bounds’ enterprise clients.As part of the collaboration, Wearable Devices will integrate its Mudra products as premium accessories for Meta-Bounds’ customers. The company added that the partnership may expand to include customized resale solutions, directly integrated across Meta-Bounds’ broader AR product portfolio.<h2 class="st-heading-2">Partnership Results To Be Showcased Later This Year</h2>Wearable Devices stated that it plans to showcase the results of its partnership with Meta-Bounds at the Augmented World Expo 2026 in Long Beach, California, scheduled for June 15-18, 2026.The Israeli company offers neural input products for both wrist-worn devices and brain-computer interfaces.Meta-Bounds has collaborated with SoftBank Group, Baidu, Oppo, Lenovo, and other large enterprise clients for its AR glasses.Wearable Devices announced an expansion of its AI advisory board in March this year, onboarding former executives from Alphabet Inc. (GOOG, GOOGL) and Qualcomm Corp. (QCOM) to help the company with its non-invasive electromyography (EMG) neural AI platform.<h2 class="st-heading-2">Global AR Market Projected To Grow To $2.3 Trillion By 2034</h2>According to a report by Fortune Business Insights, the global AR market is projected to grow to $2.3 trillion by 2034, up from $140 billion in 2025.The North American market dominated in 2025, according to the report, accounting for nearly 31% of the $140 billion industry.The increasing adoption of AR technology in the healthcare sector is expected to drive growth in the AR market, according to the report.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/WLDS">Wearable Devices</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user stated that this is just the beginning and that the rally could run for multiple days.<stembedurl>https://stocktwits.com/KF2015/message/650791498</stembedurl><a href="https://stocktwits.com/symbol/WLDS">WLDS stock</a> is down 21% year-to-date and 52% over the past 12 months. The SVanguard Extended Market Index Fund ETF (VXF) is up 40% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-tariff-refund-live-166b-who-is-eligible/cZBdLItRIzX">Trump Tariff Refund Portal Is Now Live — Who All Qualify For Claims Worth $166B?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of GLSI rise premarket on Monday (Representative image: Getty Images)

WLDS Stock Skyrockets To Best Intraday Gains In Over 7 Months — What Is Fueling The Rally?

Wearable Devices announced a collaboration with Meta-Bounds and also stated that it will develop solutions to make it easier for consumers to use AR glasses, creating a seamless user experience.

<ul class="summary-bullets"><li>In a joint letter to shareholders, Eric Jackson said the company deployed $18 million into its second-generation hedging strategy focused on multi-asset allocation.</li><li>He stated the strategy returned 5.69% during the month, while the S&amp;P 500 declined 4.98%.</li><li>He added that the planned acquisition by SRx Health Solutions is progressing through regulatory review following an SEC filing.</li></ul>Eric Jackson, the incoming CEO of SRx Health Solutions (SRXH), following its acquisition of EMJX, said on Friday that that EMJX’s digital asset treasury strategy outperformed the S&amp;P 500 by over 10% in March.“We deployed $18 million into our second-generation digital asset treasury hedging strategy, delivering a 5.69% return in March 2026 compared to a 4.98% decline in the S&amp;P 500 index amid ongoing global uncertainty,” he wrote in a letter to SRXH and EMJX shareholders. “Through mid-April, we achieved approximate gains of 3.5% and 8% in our hedging pool and long treasury investment holdings, respectively.”&nbsp;The letter comes after the company announced on Thursday acquired shares in the open market of Compass Inc. (COMP) and increased its investment in Opendoor Technologies Inc. (OPEN).<a href="https://stocktwits.com/symbol/SRXH/">SRXH’s stock</a> rose 2.6% in morning trade, with retail sentiment around the company on Stocktwits trending in the ‘bullish’ zone and chatter at ‘high’ levels over the past day.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_17_102414_png_005fb94e42.webp" alt="Screenshot 2026-04-17 102414.png" width="1279" height="150"><figcaption>SRXH retail sentiment and message volume on April 17 as of 10:30 a.m. ET | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/COMP">COMPs’ stock</a> rose nearly 10% in morning trade, while&nbsp;<a href="https://stocktwits.com/symbol/OPEN/">OPEN’s stock</a> rose over 4%. Retail sentiment around Compass trended in the ‘bullish’ zone, while sentiment around Opendoor rose to ‘extremely bullish’ from the ‘bullish’ zone over the past day. Chatter for both remained at ‘high’ levels.&nbsp;<h2 class="st-heading-2">EMJX Strategy Posts Gains While Equities Decline</h2>Jackson said recent performance reflects progress in building what he described as a more institutional approach to digital asset treasury management. The strategy combines quantitative models, artificial intelligence, and systematic risk controls to allocate capital across multiple assets.He positioned this “Gen2” framework as an evolution from earlier treasury models that were more concentrated in single assets, aiming instead to reduce drawdowns and manage risk more actively across market cycles.<h2 class="st-heading-2">Merger With SRx Health Solutions Moves Forward</h2>The acquisition, first announced in December, is now moving through regulatory review. Jackson said the companies are working to complete the transaction as soon as possible. Once closed, EMJX will operate as a wholly owned subsidiary of SRXH.“I am proud of the performance that it is delivering so far and I am thrilled to show what we can do in the future,” Jackson wrote.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-reclaims-76-k-hits-two-month-high/cZJUn1wRIxn">Bitcoin Reclaims $76K, Hits Two-Month High After Trump Signals Iran War May End Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of Bitcoin with stock market data. (Source: Andriy Onufriyenko/Getty Images)

Eric Jackson Claims Crypto Treasury Play EMJX Outpaced S&P 500 By 10% Ahead Of SRx Health Merger

The letter to shareholders comes after the company announced it had increased its stake in Open Door Technologies Inc. and added Compass Inc. shares to its holdings on Thursday.

SRx Health Incoming CEO Says EMJX Strategy Beat S&P 500 By Over 10% In March

Cryptocurrency

The letter to shareholders comes after the company announced it had increased its stake in Open Door Technologies Inc. and added Compass Inc. shares to its holdings on Thursday.


<ul class="summary-bullets"><li>Myseum.AI stated that it is developing privacy-first AI agents to help its users manage their personal media, such as photos, videos, and messages.</li><li>The company stated that these AI agents will be localized and that the company will not share information with traditional AI models.</li><li>Myseum.AI stated that its AI agentic model uses technology that adapts to an individual user’s patterns and preferences.</li></ul>Myseum.AI Inc. (MYSE) shares soared more than 200% in Thursday’s pre-market trade, on track to register its best day in more than 15 months after the company announced a strategic pivot to artificial intelligence-powered agents.The company also announced that it is rebranding to Myseum.AI from Myseum, effective April 15, 2026.If the pre-market momentum in&nbsp;<a href="https://stocktwits.com/symbol/MYSE">Myseum.AI shares</a> carries into the regular trading session, this will be the biggest move in the stock since January 2025 when MYSE soared nearly 356%.<h2 class="st-heading-2">All About Myseum.AI’s Pivot</h2>Myseum.AI stated that it is developing privacy-first AI agents to help its users manage their personal media, such as photos, videos, and messages. The company stated that these AI agents will be localized and that the company will not share information with traditional AI models.Myseum.AI stated that its AI agentic model uses technology that adapts to an individual user’s patterns and preferences.“As a privacy-first AI and social media technology company, we continue to deliver on our commitment to innovation in the secure digital media space through our development of popular privacy-first user platforms,” said Myseum.AI CEO Darin Myman.The company will continue to trade on the Nasdaq under the ticker symbol “MYSE”.Myseum.AI has multiple media and messaging apps for iPhones and Android smartphones. The company operates the Picture Party app, a private social network that lets individuals, groups, and families store and share photos and videos.It also operates a messaging app named DatChat, with some privacy-focused features such as deleting messages or chats from the sender’s device after they're sent, controlling how long messages can be viewed, and preventing screenshots.The company’s AI pivot coincides with another company, Allbirds Inc. (BIRD),&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/allbirds-bird-stock-soars-ai-pivot-50m-financing/cZJtXVbRIwe">announcing</a> a major strategic change from footwear to an AI compute provider on Wednesday.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MYSE">Myseum.AI</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/MYSE">MYSE stock</a> is down 16% year-to-date and 40% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 36% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hood-stock-extends-rally-robinhood-benefit-sec-25000-day-trading-goldman/cZJtjoYRIwZ">Robinhood To Benefit From Retail Trading Tailwinds As SEC Removes $25,000 Day Trading Restrictions, Says Goldman — HOOD Stock Extends Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

MYSE Stock Is Up More Than 200% Pre-Market Today — What’s Fueling The Rally?

Myseum.AI announced a strategic pivot to AI-powered agents that will be integrated across its social media and messaging apps.

Why Did MYSE Stock Double Pre-Market Today?

<ul class="summary-bullets"><li>HT-VA outperformed Danish drug Novo Nordisk’s blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said.</li><li>The company is now looking to advance the drug in additional preclinical validation studies.</li></ul> Shares of Hoth Therapeutics, Inc. (HOTH) jumped 70% after-hours on Monday after data from the company’s preclinical trial evaluating its experimental treatment HT-VA showed significant improvements in key genes responsible for fat production and fat metabolism.The company said that the trial showed statistically significant reduction in genes driving fat production and increased fat metabolism, positioning HT-VA as therapy for metabolic-associated fatty liver disease and obesity.The company is now looking to advance the drug in additional preclinical validation studies and evaluate clinical development pathways for metabolic and liver diseases, while also exploring strategic partnerships and collaborations to accelerate development.<h2 class="st-heading-2">Study Takeaways</h2>HT-VA outperformed Danish drug Novo Nordisk’s (NVO) blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said, while adding that it also demonstrated broad metabolic impact at the genetic levels beyond just weight reduction."These results demonstrate that GDNF (HT-VA) is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists," said CEO Robb Knie.HT-VA is part of Hoth’s efforts to move beyond its core dermatology and oncology pipeline, which includes candidates aimed at treating atopic dermatitis and mast-cell derived cancers.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around HOTH stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user expressed optimism for the rally driving the share price past the $1 mark.<stembedurl>https://www.stocktwits.com/Avi_thind/message/650169883</stembedurl><a href="https://stocktwits.com/symbol/HOTH">HOTH stock</a> has lost 38% of its value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/syre-stock-marks-best-session-in-about-3-years/cZJ8B3cRIuw">SYRE Stock Marks Best Session In About 3 Years — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is HOTH Stock Up 70% After-Hours Today?

Hoth Therapeutics said that its preclinical trial evaluating its experimental treatment HT-VA showed significant improvements in key genes responsible for fat production and fat metabolism. 

Should Vanguard Extended Market Index Fund ETF Shares (VXF) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Plus has appointed Eric J. Daniels as its chief development officer, effective April 20.</li><li>The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.</li></ul>Shares of Plus Therapeutics Inc. (PSTV) rallied 24% on Friday on the heels of the company announcing the appointment of a new chief development officer (CDO) and the U.S. Food and Drug Administration granting its experimental therapy an orphan drug designation.The stock is on track to record its best week since late September if the gains hold.Plus Therapeutics announced a 1-for-25 stock split last month in a bid to meet Nasdaq’s requirements for minimum share price for continued trading on the bourse. The stock began trading on a post-split basis on April 2.Houston, Texas-headquartered Plus has since announced that it has appointed Eric J. Daniels as its CDO, effective April 20. Daniels most recently was CDO at Kiora Pharmaceuticals, overseeing the company’s clinical, preclinical, and Chemistry, Manufacturing, and Controls (CMC) activities, Plus said.The company also said earlier this week that the FDA has granted Orphan Drug Designation to its radiotherapeutic REYOBIQ for the treatment of pediatric malignant gliomas, or aggressive brain tumors.Orphan Drug Designation is granted by the FDA to investigational therapies intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation provides several potential benefits including tax credits, fee waivers, and potential market exclusivity.The company also said that it received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PSTV stock stayed within the ‘extremely bullish’ territory over the past 12 months, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed pessimism about the company’s new CDO appointment, noting that Kiora shares slumped over the past year.<stembedurl>https://www.stocktwits.com/andre82/message/649952051</stembedurl>Yet another, however, said that the stock is very undervalued.<stembedurl>https://www.stocktwits.com/RadioIsotope25/message/649951802</stembedurl><a href="https://stocktwits.com/symbol/PSTV">PSTV stock</a> has dropped about 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF